15,377 Shares in NewAmsterdam Pharma Company N.V. $NAMS Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D purchased a new position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,377 shares of the company’s stock, valued at approximately $539,000.

Other institutional investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its holdings in shares of NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after buying an additional 708 shares in the last quarter. Wolverine Asset Management LLC bought a new stake in NewAmsterdam Pharma in the 3rd quarter valued at $69,000. NBC Securities Inc. purchased a new stake in NewAmsterdam Pharma in the 4th quarter worth $86,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in NewAmsterdam Pharma by 26.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after purchasing an additional 1,156 shares in the last quarter. Finally, Simon Quick Advisors LLC bought a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $202,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Louis G. Lange sold 44,619 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the transaction, the director owned 10,360 shares of the company’s stock, valued at $315,151.20. This represents a 81.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the transaction, the insider owned 69,302 shares in the company, valued at $2,099,850.60. The trade was a 60.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,168,286 shares of company stock worth $38,211,967 in the last three months. Corporate insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $39.59 on Tuesday. The firm has a market capitalization of $4.55 billion, a P/E ratio of -22.12 and a beta of 0.02. NewAmsterdam Pharma Company N.V. has a 52-week low of $16.78 and a 52-week high of $42.21. The stock has a 50 day moving average price of $31.95 and a 200 day moving average price of $34.27.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.81 EPS for the current year.

Analysts Set New Price Targets

NAMS has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Needham & Company LLC increased their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Truist Financial initiated coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $48.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.